CAITLYN KRUSINSKY: Open Payments
NPI 1376388041 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,797 in 105 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $803 · 2025 $1,797
Food & beverage: $1,797
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $245 |
| Janssen Pharmaceuticals, Inc | 13 | $240 |
| ABBVIE INC. | 24 | $230 |
| Teva Pharmaceuticals USA, Inc. | 11 | $184 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Vanda Pharmaceuticals Inc. | 5 | $145 |
| Lundbeck LLC | 5 | $88 |
| Almatica Pharma LLC | 5 | $84 |
| Soleno Therapeutics, Inc. | 2 | $62 |
| Axsome Therapeutics, Inc. | 3 | $51 |
Products named: INGREZZA, REXULTI, VRAYLAR, INVEGA SUSTENNA, FANAPT, UZEDY, LOREEV XR, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
